Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. Based on world-leading Scottish microRNA research and technology, SistemTOX™ filters out potentially harmful compounds early in the development process, helping to save millions of pounds in costs.
“Building on leading Scottish research expertise, SistemTOX™ uses microRNA profiling to decipher, early on, potential toxicity. Furthermore, It is not just a yes/no answer, it also provides context which feeds important information quickly back to the scientists. Basically it places the power back into the developer's hands and reduces risk.”
The launch of SistemTOX™ comes at a time when the industry has been experiencing huge issues with compound toxicity. Sistemic CEO Professor Chris Hillier stated "Building on leading Scottish research expertise, SistemTOX™ uses microRNA profiling to decipher, early on, potential toxicity. Furthermore, It is not just a yes/no answer, it also provides context which feeds important information quickly back to the scientists. Basically it places the power back into the developer's hands and reduces risk."
SistemTOX™ has already been extensively evaluated with selected partners and is another exciting development from one of Scotland's fastest growing life science companies.
Research reveals Ghanaian children face high cancer risk from local fish